Vergleich

Anti-Human PD-L1 (CD274) (Clone 130021) - 100 µg

ArtNr LEIN-B568-100ug
Hersteller Leinco Technologies
Menge 100 ug
Quantity options 100 ug 25 ug
Kategorie
Typ Antibody Monoclonal
Applikationen FC, IHC
Clon 130021
Specific against Human (Homo sapiens)
Host Mouse
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Versandbedingung Raumtemperatur
Lieferbar
Manufacturer - Applications
CyTOF®, FC, IHC
Manufacturer - Category
Primary Monoclonal Antibodies>Growth Factors and Cytokines|Primary Monoclonal Antibodies>Immune Checkpoints
Manufacturer - Targets
PD-L1
Country of Origin
USA
Shipping Temperature
Next Day Ambient
Storage Conditions
The lyophilized antibody can be stored desiccated at -20°C to -70°C for up to twelve months. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid repeated freeze thaw cycles. No detectable loss of activity was observed after six months.
Product Description
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Background
PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a coinhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Other Applications Reported In Literature
Immunohistochemistry: Suitable for use at concentration of 8-25 µg/mL.
CyTOF-ready:Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
PubMed
PD-L1
Manufacturer - Specificity
Clone 130021 recognizes an epitope on human B7-H1. In direct ELISAs, this antibody shows no cross-reactivity with rhB7-1, rhB7-2, rhB7-H2, rhB7-H3, rmB7-H1 or rmPD-L2.
RRID
AB_2828240
Formulation
This monoclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco's phosphate buffered saline (1X PBS) pH 6.4 containing 5.0% w/v trehalose with no calcium, magnesium or preservatives present.
Antigen Distribution
PD-L1 is present on T cells, B cells, NK cells, dendritic cells, IFN-γ activated endothelial cells, and monocytes.
Immunogen
Purified Recombinant Human CD274/PD-L1 (Accession # Q9NZQ7)
Additional Information
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Keywords
B7-H, B7H1, B7-H1, B7H1PDCD1L1, CD274 antigenMGC142294, CD274 molecule, CD274, PDCD1L1, PDCD1LG1, PDCD1LG1MGC142296, PDL1, PD-L1, PD-L1B7 homolog 1, PDL1PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H, B7-H1, B7H1, human CD274, CD274 antigen, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, human Programmed cell death 1 ligand 1, human programmed death ligand 1, A530045L16Rik, B7h1, Cd274, Pdcd1l1, Pdcd1lg1, human Pdl1

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Menge: 100 ug
Lieferbar: In stock
lieferbar

Vergleichen

Auf den Wunschzettel

Angebot anfordern

Lieferzeit anfragen

Technische Frage stellen

Bulk-Anfrage stellen

Fragen zum Produkt?
 
Schließen